News Releases

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 11, 2026

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

May 05, 2026

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 24, 2026

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Mar 17, 2026

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Feb 26, 2026

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

Jan 29, 2026

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

Jan 06, 2026

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

Jan 05, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200